Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews, September 2013

Executive Summary

This Month's Profile Group: Central Venous Access: Start-Ups Change The Standard Of Care, features profiles of Bio 2 Medical, Houston Medical Robotics, and Mirador Biomedical. Plus these Start-Ups Across Health Care: BioVerys, Clinmet, Eclipse Breast Health Technologies, and Sea Lane Biotechnologies.

You may also be interested in...



Eclipse Breast Health Technologies Inc.

Eclipse Breast Health Technologies Inc. is developing an inexpensive, at-home self-examination device to aid in the early detection of breast cancer. The noninvasive, handheld Eclipse device does not use radiation, and is completely painless so women can use it as often as they choose, without any risk of side effects.

Mirador Biomedical Inc.

During insertion of central venous catheters, physicians may unintentionally advance into an artery rather than the desired vein, an error that can cause serious complications, even death. Mirador Biomedical Inc. aims to improve the safety of central venous access with its Compass platform, battery-powered, pressure-measurement devices that can rapidly detect the difference in pressures between arteries and veins.

BiO2 Medical Inc.

Hospitalized patients are at the greatest risk for a fatal pulmonary embolism within the first 10 days after admission, but traditional inferior vena cava filters to prevent PEs if anticoagulant therapy is contraindicated and/or ineffective are not typically placed in a patient until approximately one week into their hospital stay. BiO2 Medical Inc. is looking to address this treatment gap with its Angel Catheter, a device that incorporates the PE protection of a retrievable, self-expanding nitinol IVC filter attached to a triple-lumen, central venous access catheter.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel